Epigenetic Modifications in Cancer: A Laboratory Perspective on DNA Methylation Biomarkers

Epigenetic alterations, especially aberrant DNA methylation, represent fundamental hallmarks of cancer that contribute to tumor initiation, progression, and metastasis without altering the underlying DNA sequence. In cancer cells, hypermethylation of CpG islands within promoter regions frequently silences tumor suppressor genes such as p۱۶, MGMT, and GSTP۱, while global hypomethylation leads to genomic instability and inappropriate activation of oncogenes and transposable elements. This laboratory-oriented perspective examines the translational potential of DNA methylation biomarkers for improved cancer detection, prognosis, and therapeutic monitoring, with particular emphasis on practical implementation in clinical diagnostic settings. Key biomarkers including SEPT۹ for colorectal cancer (the basis of the FDA-approved Epi proColon test), SHOX۲ and PTGER۴ for lung cancer, MGMT as a predictive marker for temozolomide response in glioblastoma, and GSTP۱ for prostate cancer detection are critically reviewed. Laboratory methodologies ranging from traditional bisulfite conversion coupled with quantitative methylation-specific PCR (qMSP) and pyrosequencing to advanced approaches such as reduced representation bisulfite sequencing (RRBS), whole-genome bisulfite sequencing (WGBS), enzymatic methyl-seq (EM-seq), and digital PCR are discussed in detail, highlighting their sensitivity, specificity, throughput, and suitability for liquid biopsy applications using circulating cell-free DNA (cfDNA). Challenges in clinical translation—including DNA degradation during bisulfite treatment, low tumor-derived DNA fractions in plasma, tumor heterogeneity, standardization across laboratories, and the need for robust bioinformatics pipelines—are addressed alongside emerging solutions such as multi-omics integration and machine learning algorithms for enhanced diagnostic accuracy and tissue-of-origin prediction. Overall, DNA methylation analysis offers a stable, early-appearing, and minimally invasive tool that complements genetic testing, with significant promise for early cancer screening and personalized medicine, particularly when validated in diverse populations

کلیدواژه ها:

DNA methylation ، Epigenetic biomarkers ، Cancer diagnostics ، Liquid biopsy ، Laboratory methods